RNA interference compositions and methods for malignant tumors
USRE48887E1 · kind E1 · reissue
1Cited by
11References
35Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 19, 2019 |
| Grant date | Jan 11, 2022 |
| Priority date | — |
| Expiry date | Sep 19, 2039 |
Classification
- Technology area (CPC —)General
Abstract
This invention provides compositions for use in distributing active agents for treating a malignant tumor in a subject. The compositions contain RNAi molecules targeted to a human GST-π, along with RNAi molecules targeted to a human p21, and a pharmaceutically acceptable carrier. The carrier can include nanoparticles composed of an ionizable lipid, a structural lipid, one or more stabilizer lipids, and a lipid for reducing immunogenicity of the nanoparticles. This invention further provides methods for preventing or treating a malignant tumor by administering a therapeutically effective amount of an RNAi composition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.